How to Cite:
Aljarari, R. M. (2022). The dilemma of peanut allergy: An overview. *International Journal of Health Sciences*, *6*(S6), 11418–11423. https://doi.org/10.53730/ijhs.v6nS6.13172

The dilemma of peanut allergy: An overview

Rabab Mohamed Aljarari
Department of biology, College of Science, University of Jeddah, Jeddah, Saudi Arabia

Abstract---The peanut food allergy, which is often an immunological allergy based on patient ingestion of peanut, is a significant food allergy. Different forms of allergy exist for both children and adults depending on the allergen. The fundamental methods for diagnosing a peanut allergy are blood and physical testing. Keys for understanding peanut allergy physiology, various etiology, immunological reactions, and diagnosis are introduced in this overview.

Keywords---peanut, allergy, hypersensitivity, allergens.

Introduction

Contradictory dietary response may be divided into two categories (immune-related and non-immune-related). The definition of a food allergy is "an immunologic response brought on by the consumption of a food or food added substance. " by the American Academy of Allergy and Immunology (AAAI), whereas food prejudice is defined as "an overall term showing a mysterious physiological reaction to a consumed food or food added substance that isn't revealed to be immunogenic" (1). Food allergy is an unpredictable, invulnerable response to food, a form of exterior extreme touchiness. In this type of reaction, an allergen—a dietary protein or a protein with a non-amino corrosive portion, such starch—inadvertently sets off the immune system. Additionally, dietary allergies are often ingested and typically resist acidic pH of stomach, high temperatures, and protein processing in the gastrointestinal tract. In any event, a current study discovered that there was no conclusive link between protein allergenicity and in vitro absorbability. Children are more likely than adults to have a food allergy. (2).

The peanut

Ground nuts, earth nuts, and monkey nuts are additional names for peanuts. Only the word "peanut" will be used in this report. Without qualification, Any use of the word "nut" shall mean only tree nuts, such as hazel, Brazil, or almond, not peanuts. Arachis hypogaea, the plant that produces peanuts, owned to the Leguminosae group. The plant produces pods with seeds within that are typically known as peanuts (3). Green peas, soybeans, kidney beans, and lentils are some

examples of different staples that come from plants that belong to the same plant family (4). As a vegetable, the peanut has no inherent affinity for nuts like hazel, Brazil, or almond. Although it is a South American native, it has been developed in places including Europe, Africa, North America, and India (5).

Peanuts typically contain 46% fat, 26% protein (albumins and globulins), and 13% starch in terms of their nutritional makeup (6). The globulin proteins are separated into arachidonic and non-arachidonic divisions, contrasting local arachin protein, which has a sub-atomic burden of >600,000 daltons. These two divisions have been divided into different subunits. (7). Lectin-responsive glycoproteins, protease inhibitors, Gka-amylase inhibitors, phospholipases, and agglutinins make up the majority of the protein in egg whites. Some peanut proteins can make unprotected people extremely touchy, a true sort of food allergy that, in some cases, can be fatal (8). Alluded to as peanut allergies, these proteins. They designated "Peanut 1" as the main, isolated peanut allergy. Two substantial peanut allergies, particular Ara h II and Ara h I, were found after more research. The isoelectric focuses and sub-atomic loads of these glycoproteins are 4.55 and 63,500 Daltons and 5.2 and 17,000 Daltons, respectively (9).

Peanut allergy development

The undesirable health impacts that may arise from the activation of a particular invulnerable reaction are referred to as allergies. (10-13). Hypersensitive illness typically develops in two phases and may affect a variety of tissues. The primary step, sharpening, occurs when a helpless person is unintentionally exposed to an actuating allergen in adequate amounts to trigger a necessary safe reaction (14). If the sensitive person is exposed to the same allergen again later, a quicker and stronger immune response may be elicited, which might result in a provocative severe itchiness response in the relevant objective organ or organs (15).

The allergen concentrations required to either initiate or inspire a negatively sensitive reaction are often unknown. When it comes to the basic immunobiological processes that are triggered after receiving the immunogenic sign, negatively susceptible reactions don't differ much from defensively insusceptible reactions. high levels of IgE and Eosinophilia, which are also signs of a hypersensitive reaction, are associated with human invulnerable responses to parasitic worm illnesses of the gastrointestinal tract. The allergen should be experienced in adequate amounts. and structure for the receptive T cells to recognize it (16-18).

The delivery of an immunogenic boost and crucial costimulatory signals by particular antigen-presenting cells (APC) is required for the implementation of these phones. Dendritic cells (DC) are considered the main APCs because they promote the activation of the crucial resistance reaction and enhancement of unfavorable susceptible refinement. (19). These cells are present in minor amounts in lymphoid tissue, the skin's epithelial layers (Langerhans cells), the gastrointestinal and respiratory systems. DC serve as the resistant framework's watchmen in these last tissues. They conceal, cycle, and subsequently deliver antigen to receptive T cells in an immunogenic form (20).

Even though the majority of foreign proteins are potentially immunogenic, even a little amount can alter the form of the immune response required for negatively susceptible sharpening. Understanding the elements of allergy requires understanding the characteristics of hypersensitive reactions as well as how they are triggered and treated. A counteracting substance (immunoglobulin) of the IgE class influences a number of hypersensitive reaction types, notably those that have a sudden onset, like peanut allergy (21).

The vulnerable person will mount a specific IgE neutralizer response after initial exposure to the allergen. These antibodies target pole cells, involving those in the respiratory and gastrointestinal tracts, fundamentally and collaborate with them. Now that the person has been sharpened, exposure to the allergen will cause a rapid form of touchiness (hypersensitive) reaction (22). The allergen causes pole cell degranulation and the appearance of both previously created and freshly blended arbiters by cross-joining IgE antibodies linked to high proclivity receptors on pole cells. Together, these actions result in bronchoconstriction, vasodilation, and other hypersensitive response-related features (3).

T cells are essential for the production of the IgE immunizer and are tightly controlled. IgE responses are triggered and supported by administrative cytokines that have a related relationship to T lymphocytes, B lymphocytes, and other immune system cells. The cytokine interleukin 4 (IL-4), which has been demonstrated in mice to be necessary for proper IgE responses, is of particular relevance (23). Mice without the ability to produce IL-4 do not exhibit IgE responses, whereas mice carrying the IL-4 transgene exhibit increased blood IgE levels and mount more vigorous IgE immunizer reaction (9). IFN-g, a cytokine that irritates IgE neutralizing antibody production, provides an equilibrium. These similar cytokines also act to modulate the induction of IgE reactions proportionally. in humans38, despite the fact that another cytokine, interleukin 13 (IL-13), which resembles IL-4 in some ways, also have a substantial function in promoting the production of IgE in people (6).

Properties of peanut allergy

It is widely acknowledged that specific IgE is produced against various peanut allergens. There are differences in how different persons interpret the extent of peanut allergies. A large number of these allergens are heat stable. and warming or prepping them has little effect on how allergic they are. In this manner, consumption of raw or heated peanuts and peanut products might cause a hypersensitive reaction. Studies have shown that compared to non-unfavorably sensitive control participants, individuals with peanut allergies have higher rates of peanut-specific T lymphocytes in their blood (24-27). The idea that IFN-g regulation plays a significant role in the pathophysiology of peanut allergy, supernatants obtained from peripheral blood mononuclear cells of peanut adversely susceptible individuals that were activated by peanut allergen contained significantly less IFN-g than control societies. Researchers looked at T lymphocyte responses to tree-nut and peanut allergens in vitro. With one exception, peanut-receptive T lymphocytes clones grew in vitro in the presence of peanut concentrate and revealed cross-reactivity with hazelnut or Brazil allergens (10).

The clones of peanut-explicit T cells generated large amounts of IL-4 but very modest amounts of IFN-g, a regular pattern of aggregation of a certain Th2-type together with the emergence of IgE allergy reactions. Comparative findings were explained by comparing versus controls, showing that patients who were more sensitive to peanuts had more CD4+ T lymphocytes that responded to peanuts and that These cells generated less IFN-g and more IL-4. All of the evidence points to a connection between peanut allergy and an increase in Th2-type cells that secrete considerable amounts of IL-4 (28).

Peanut allergy determination and diagnosis

The next step would be to evaluate a research facility or a clinical system to confirm the outcome of differential analysis. The prick skin test (PST) is a more prevalent clinical method for determining peanut allergy, whereas the fluoroenzyme immunoassay (Pharmacia Immuno CAP-FEIA) is often utilized for research centre evaluation. In the PST, the prick technique is used to apply peanut concentrations, a saline (negative control), and a histamine (positive control). When the evoked wheals are at least 3 mm greater than those produced by the negative controls, they are regarded as definite. (29). The second evaluation, called Immuno CAP-FEIA, examines the patient's blood levels of peanut-explicit IgE. A robust network is used to cover peanut allergens, and a serum test is then conducted. If a case has IgE antibodies versus peanut allergens in their blood, they linked to fixed peanut allergens and may be identified by a marked auxiliary antibody particular for human IgE (5).

The oral peanut test is necessary in cases where a conclusive finding is impossible. Three types of oral food challenges can be distinguished: openly done (case and healthcare provider both understand the test material), single-daze (only the healthcare professional understand the test substance), and double visually impaired and fake treatment-controlled food challenges (wellness care provider and case have no idea what the test content is). Due to its thoroughness and lack of emotion, DBPCFC is the "best quality level" for detecting food sensitivities (30-31). If the reaction to DBPCFC is positive, peanut should not be consumed because it is recognized as a hypersensitive food. If the case's reaction to the DBPCFC is negative, they can reintroduce peanuts because they are resilient to them. The oral test should be administered in a clinic by trained medical personnel, admission to crisis care, and prescriptions since there is a risk of triggering major allergic reactions. If the case has a history of particularly significant responses to peanuts the test tests may not typically be carried out (7).

Conclusion

Peanut allergy is one of the more prevalent food allergies. The results of blood tests such the ELISA as well as the symptoms and physical characteristics of the patient help to make the diagnosis of peanut allergy.

References

1. Anagnostou, K., & Clark, A. (2015). The management of peanut allergy. Archives of disease in childhood, 100(1), 68-72.

2. Brough, H. A., Simpson, A., Makinson, K., Hankinson, J., Brown, S., Douiri, A., ... & Lack, G. (2014). Peanut allergy: effect of environmental peanut exposure in children with filaggrin loss-of-function mutations. Journal of Allergy and Clinical Immunology, 134(4), 867-875.
3. Cherkaoui, S., Ben-Shoshan, M., Alizadehfar, R., Asai, Y., Chan, E., Cheuk, S., ... & Clarke, A. (2015). Accidental exposures to peanut in a large cohort of Canadian children with peanut allergy. Clinical and translational allergy, 5(1), 1-6.
4. Dang, T. D., Tang, M., Choo, S., Licciardi, P. V., Koplin, J. J., Martin, P. E., ... & Allen, K. J. (2012). Increasing the accuracy of peanut allergy diagnosis by using Ara h 2. Journal of allergy and clinical immunology, 129(4), 1056-1063.
5. Du Toit, G., Roberts, G., Sayre, P. H., Bahnson, H. T., Radulovic, S., Santos, A. F., ... & Lack, G. (2015). Randomized trial of peanut consumption in infants at risk for peanut allergy. N Engl J Med, 372, 803-813.
6. Du Toit, G., Roberts, G., Sayre, P. H., Plaut, M., Bahnson, H. T., Mitchell, H., ... & Learning Early About Peanut Allergy (LEAP) Study Team. (2013). Identifying infants at high risk of peanut allergy: the Learning Early About Peanut Allergy (LEAP) screening study. Journal of Allergy and Clinical Immunology, 131(1), 135-143.
7. Du Toit, G., Sayre, P. H., Roberts, G., Sever, M. L., Lawson, K., Bahnson, H. T., ... & Lack, G. (2016). Effect of avoidance on peanut allergy after early peanut consumption. New England Journal of Medicine, 374(15), 1435-1443.
8. Ebisawa, M., Ito, K., & Fujisawa, T. (2020). Japanese guidelines for food allergy 2020. Allergology International, 69(3), 370-386.
9. Finkelman, F. D. (2010). Peanut allergy and anaphylaxis. Current opinion in immunology, 22(6), 783-788.
10. Fisher, H. R., Keet, C. A., Lack, G., & du Toit, G. (2019). Preventing peanut allergy: where are we now?. The Journal of Allergy and Clinical Immunology: In Practice, 7(2), 367-373.
11. Fleischer, D. M., Sicherer, S., Greenhawt, M., Campbell, D., Chan, E., Muraro, A., ... & Rosenwasser, L. (2015). Consensus communication on early peanut introduction and the prevention of peanut allergy in high-risk infants. Pediatrics, 136(3), 600-604.
12. Greenhawt, M., Shaker, M., Wang, J., Oppenheimer, J. J., Sicherer, S., Keet, C., ... & Wallace, D. (2020). Peanut allergy diagnosis: A 2020 practice parameter update, systematic review, and GRADE analysis. Journal of Allergy and Clinical Immunology, 146(6), 1302-1334.
13. Hourihane, J. O. B. (2011). Peanut allergy. Pediatric Clinics, 58(2), 445-458.
14. Iweala, O. I., Choudhary, S. K., & Commins, S. P. (2018). Food allergy. Current gastroenterology reports, 20(5), 1-6.
15. Kotz, D., Simpson, C. R., & Sheikh, A. (2011). Incidence, prevalence, and trends of general practitioner–recorded diagnosis of peanut allergy in England, 2001 to 2005. Journal of Allergy and Clinical Immunology, 127(3), 623-630.
16. Krogulska, A., & Wood, R. A. (2020). Peanut allergy diagnosis: Moving from basic to more elegant testing. Pediatric Allergy and Immunology, 31(4), 346-357.

17. Lieberman, J. A., Gupta, R. S., Knibb, R. C., Haselkorn, T., Tilles, S., Mack, D. P., & Pouessel, G. (2021). The global burden of illness of peanut allergy: A comprehensive literature review. Allergy, 76(5), 1367-1384.
18. Mueller, G. A., Maleki, S. J., & Pedersen, L. C. (2014). The molecular basis of peanut allergy. Current allergy and asthma reports, 14(5), 1-9.
19. Neuman-Sunshine, D. L., Eckman, J. A., Keet, C. A., Matsui, E. C., Peng, R. D., Lenehan, P. J., & Wood, R. A. (2012). The natural history of persistent peanut allergy. Annals of Allergy, Asthma & Immunology, 108(5), 326-331.
20. Nguyen-Luu, N. U., Ben-Shoshan, M., Alizadehfar, R., Joseph, L., Harada, L., Allen, M., ... & Clarke, A. (2012). Inadvertent exposures in children with peanut allergy. Pediatric Allergy and Immunology, 23(2), 134-140.
21. Nicolaou, N., Murray, C., Belgrave, D., Poorafshar, M., Simpson, A., & Custovic, A. (2011). Quantification of specific IgE to whole peanut extract and peanut components in prediction of peanut allergy. Journal of Allergy and Clinical Immunology, 127(3), 684-685.
22. Nowak-Wegrzyn, A., Hass, S. L., Donelson, S. M., Robison, D., Cameron, A., Etschmaier, M., ... & McCann, W. A. (2021). The Peanut Allergy Burden Study: impact on the quality of life of patients and caregivers. World Allergy Organization Journal, 14(2), 100512.
23. Palladino, C., & Breiteneder, H. (2018). Peanut allergens. Molecular immunology, 100, 58-70.
24. Peters, R. L., Allen, K. J., Dharmage, S. C., Koplin, J. J., Dang, T., Tilbrook, K. P., ... & Gurrin, L. C. (2015). Natural history of peanut allergy and predictors of resolution in the first 4 years of life: a population-based assessment. Journal of Allergy and Clinical Immunology, 135(5), 1257-1266.
25. Shaker, M., & Greenhawt, M. (2019). Peanut allergy: Burden of illness. In Allergy & Asthma Proceedings (Vol. 40, No. 5).
26. Sicherer, S. H., & Wood, R. A. (2013). Advances in diagnosing peanut allergy. The Journal of Allergy and Clinical Immunology: In Practice, 1(1), 1-13.
27. Togias, A., Cooper, S. F., Acebal, M. L., Assa'ad, A., Baker, J. R., Beck, L. A., ... & Boyce, J. A. (2017). Addendum guidelines for the prevention of peanut allergy in the United States: report of the National Institute of Allergy and Infectious Diseases–sponsored expert panel. World Allergy Organization Journal, 10(1), 1-18.
28. Venter, C., Hasan Arshad, S., Grundy, J., Pereira, B., Bernie Clayton, C., Voigt, K., ... & Dean, T. (2010). Time trends in the prevalence of peanut allergy: three cohorts of children from the same geographical location in the UK. Allergy, 65(1), 103-108.
29. Vereda, A., van Hage, M., Ahlstedt, S., Ibañez, M. D., Cuesta-Herranz, J., van Odijk, J., ... & Sampson, H. A. (2011). Peanut allergy: clinical and immunologic differences among patients from 3 different geographic regions. Journal of Allergy and Clinical Immunology, 127(3), 603-607.
30. Vickery, B. P., Ebisawa, M., Shreffler, W. G., & Wood, R. A. (2019). Current and future treatment of peanut allergy. The Journal of Allergy and Clinical Immunology: In Practice, 7(2), 357-365.
31. Warren, C., Lei, D., Sicherer, S., Schleimer, R., & Gupta, R. (2021). Prevalence and characteristics of peanut allergy in US adults. Journal of Allergy and Clinical Immunology, 147(6), 2263-2270.